Respiratory Syncytial Virus (RSV)
Older Adult, Elderly Vaccines Forecast
Arexvy, Abrysvo and mResvia arrived to blockbuster expectations in 2023 and 2024, then saw sales fall sharply once ACIP narrowed and then re-widened who should receive them. Now AstraZeneca, Sanofi/Vicebio and Moderna are racing to launch the next generation, combination vaccines that pair RSV protection with human metapneumovirus. This is the independent commercial assessment of where the market goes next, drawing on VacZine Analytics' long-standing, independent authority in respiratory vaccine markets.
- Format
- PDF (~375 slides) + Excel
- Coverage
- 10 high-income countries
- Vaccines assessed
- Arexvy, Abrysvo, mResvia + combos
- Forecast horizon
- To 2037
- Approach
- Scenario-based, revaccination-adjustable
- Base edition
- August 2025
- Availability
- Syndicated / bespoke
hospital admissions per year (adults)
RSV deaths per year (adults)
in adults aged over 65
at-risk 50-59 year-olds
Why RSV became an adult vaccine priority
RSV was long regarded chiefly as a paediatric threat, but it is now recognised as a major cause of severe respiratory illness in older adults, one substantial enough to justify three newly licensed vaccines within a 12 month period. Understanding that burden, and what has happened to uptake since launch, is central to understanding where the market goes from here.
Pathogen overview - Respiratory syncytial virus in older adults
Human respiratory syncytial virus (RSV) is a common respiratory virus now recognised as an important pathogen in adults, especially the elderly. In adults, approximately 1.5 million episodes of RSV-associated acute respiratory infection occur each year in industrialized countries. Globally, an estimated 336,000 hospital admissions (uncertainty range 186,000 to 614,000) and 14,000 in-hospital deaths (uncertainty range 5,000 to 50,000) have been attributed to adult RSV infection, though the true burden is believed to be higher still (Shi T et al., 2020; Kulkarni D et al., 2025). In the United States, an estimated 60,000 to 160,000 hospitalizations occur annually among persons aged over 65, with around 6,000 to 10,000 deaths (CDC, RSV-NET), again with wide variance between estimates.
Cardiovascular disease, chronic lung disease and diabetes are common underlying conditions among adults hospitalized with RSV infection, and in-hospital mortality among hospitalized adults over 18 has been estimated at approximately 12% (Shi T et al., 2022). There is no specific antiviral treatment for RSV infection; for adults who require hospitalization, supportive therapy remains the mainstay of care, which is precisely what makes prevention through vaccination so commercially and clinically significant.
GSK, Pfizer and Moderna brought three vaccines to market within a single year, Arexvy (May 2023), Abrysvo (May 2023, with an additional maternal indication) and mResvia/mRNA-1345 (May 2024), initially under ACIP's shared clinical decision-making recommendation for adults 60 and over. That recommendation proved commercially awkward: in June 2024, ACIP moved to a clearer age- and risk-based recommendation (all adults 75 and over, plus adults 60 to 74 at increased risk), and in April 2025 further expanded coverage to at-risk adults aged 50 to 59. Despite this widening eligibility, reported sales for all three vaccines fell sharply through 2024 and into 2025, as vaccination rates among eligible older adults declined faster than new risk groups were added.
Update (August 2026): The shift toward broader, risk-based eligibility is not confined to the US. Following JCVI advice, NHS England confirmed on 1 July 2026 that its year-round RSV vaccination programme will extend from 1 September 2026 to adults aged 65 to 74 with chronic respiratory disease or immunosuppression, having already widened to adults aged 80 and over and care home residents earlier in 2026 (NHS England, 1 July 2026).
Even as incumbent sales have fallen, RSV vaccine R&D remains unusually active, driven by a shared industry thesis: RSV, human metapneumovirus (hMPV) and parainfluenza virus (PIV) together are now estimated to cause as many US hospitalizations as seasonal influenza, creating a clear rationale for combination vaccines that protect against more than one respiratory pathogen in a single dose.
Blockbuster launch, sharp reset, combination-vaccine pivot
Three vaccines reached the market within a single year and each has since seen sales fall well below launch expectations. Rather than retreat, the field's next wave of competitors is betting that pairing RSV with human metapneumovirus, and potentially parainfluenza virus, is the differentiator that restores commercial momentum.
-
GSKApproved, 2026 sales reboundArexvy
Licensed May 2023 for older adults; reported FY2024 sales of approximately GBP 590 million (roughly USD 765 million), a decline of more than 50% versus the prior year, attributed largely to the narrower risk-based ACIP recommendation for adults aged 60 to 74. Update (August 2026): Q2 2026 Arexvy sales rebounded sharply to GBP 0.2 billion, growth of more than 100% year-on-year (GSK Q2 2026 results, 28 July 2026). Update (November 2026): that rebound reversed in Q3 2026, with Arexvy sales falling back to GBP 0.2 billion, down 24% year-on-year (GSK Q3 2026 results, 28 October 2026). -
PfizerApproved, 2026 sales reboundAbrysvo
Licensed May 2023, the only incumbent with an additional maternal indication. Q4 sales fell 62% year-on-year, attributed to reduced vaccination rates among eligible older adults, partly offset by strong demand in the maternal immunization setting. Update (August 2026): sales recovered to USD 208 million in Q2 2026, up 43% year-on-year on an operational basis (Pfizer Q2 2026 results, 4 August 2026). Update (November 2026): worldwide Abrysvo sales rose further to USD 303 million in Q3 2026, up 9% year-on-year, though growth was driven entirely by international markets (up from USD 68 million to USD 162 million) while US sales fell 33% to USD 141 million (Pfizer Q3 2026 results, 3 November 2026). -
ModernaApproved, early uptakemResvia (mRNA-1345)
Licensed May 2024 as the third and most recent entrant, for adults 60 and over. As the newest launch, reported sales remain modest, and it carries the least legacy exposure to the pre-2024 shared clinical decision-making recommendation. Update (August 2026): Moderna signed an EU joint-procurement framework contract for up to 24 million mResvia doses over four years, covering Austria, Denmark, Ireland, Luxembourg, Norway and Portugal ahead of the 2026/27 RSV season (European Commission, 9 July 2026). -
AstraZeneca / Sanofi-Vicebio / ModernaPhase 1-3IVX-A12, VXB-241/SPO256/SPO291, mRNA-1365 RSV + hMPV combination
AstraZeneca's Phase 3-ready protein VLP combination vaccine IVX-A12 (via its Icosavax acquisition) has shown robust immune responses against both RSV and hMPV. Sanofi, following its 1.6 billion US dollar acquisition of Vicebio, is running a Phase 1 trial of bivalent candidate VXB-241. Moderna's mRNA-1365 is in Phase 1 as an RSV/hMPV combination. Clover Pharmaceuticals' SCB-1019 rounds out the field. Update (September 2026): Clover reported positive Phase 2 data (6 September 2026) for two further RSV combination candidates, SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), from a 420-subject, placebo-controlled trial in Australian adults aged 60-85. Both candidates raised neutralizing antibodies to RSV, hMPV and PIV3 with no drop-off in responses among those aged 75 and over, no immune interference from adding the PIV3 component, and a well-tolerated safety profile; the company also cited an exploratory 62% lower rate of respiratory tract infection versus placebo during a concurrent RSV outbreak, and said it would pursue mid- and late-stage development plans and potential global partnering. Sanofi has also moved its RSV+hMPV candidate beyond Phase 1, opening a placebo-controlled Phase 2b proof-of-concept efficacy study (NCT07810010) enrolling around 8,000 adults aged 60 and over, alongside a separate Phase 1/2 dose-ranging study (NCT07734649) in around 2,400 adults of the same age group; both were listed as recruiting as of September 2026 (Sanofi clinical trials pages).
All three incumbent RSV vaccines have seen sales fall well below their initial launch trajectory, even as ACIP has progressively widened who qualifies for a dose, extending down to at-risk 50 to 59 year-olds in April 2025. That gap between eligibility and uptake is precisely the commercial tension the next wave of combination candidates from AstraZeneca, Sanofi/Vicebio and Moderna is designed to exploit. Update (August 2026): Q2 2026 results show an early, partial rebound, GSK's Arexvy and Pfizer's Abrysvo both returned to year-on-year sales growth, and Moderna secured a new EU joint-procurement contract for mResvia ahead of the 2026/27 season, though it is too soon to tell whether this marks a durable recovery or simply reflects a low prior-year base. Update (November 2026): Q3 2026 results point to an uneven picture rather than a clean recovery, GSK's Arexvy sales reversed back into a 24% year-on-year decline, while Pfizer's Abrysvo posted 9% worldwide growth driven almost entirely by international demand even as its US sales fell 33% (GSK Q3 2026 results, 28 October 2026; Pfizer Q3 2026 results, 3 November 2026). The VacZine Analytics model quantifies the commercial opportunity across multiple revaccination-schedule and combination-switching scenarios.
Six analytical layers - one commercial picture
The MarketVIEW RSV older adult analysis spans disease burden, incumbent sales performance, the combination-vaccine pipeline and scenario-based revenue forecasting across 10 high-income countries, with a specific focus on revaccination schedules and combination-product switching.
Bottom-up modelling across 10 high-income countries, public and private, with country-specific pricing analogues, at-risk stratification and cohort target ranges.
Arexvy, Abrysvo and mResvia sales performance alongside AstraZeneca's IVX-A12, Sanofi/Vicebio's VXB-241 and Moderna's mRNA-1365 combination candidates.
Explore no-revaccination, yearly, and 2, 3 and 5-yearly schedules, and their differing commercial and public-health implications.
Base, upside and conservative scenarios to 2037, including country-level switching between monovalent and combination products (dual and triple formats).
Updated global and US adult RSV burden data, underlying risk conditions, and in-hospital mortality estimates.
Product differentiators, product longevity and company-specific revenue and share estimates across USA, EU, developed ROW and emerging markets.
A glimpse of the commercial model
The table below shows a partial view of the target-population and scenario framework. Full revenue outputs, pricing assumptions and country-level data are in the licensed model.
| Target population | Geography | Vaccine type | Revaccination schedule | Revenue scenario |
|---|---|---|---|---|
| Adults 75+ (age-based) | 10 high-income countries | Monovalent RSV | No revaccination | Modelled |
| At-risk adults 50-74 | USA + EU5 | Monovalent RSV | Yearly / 3-yearly | Modelled |
| Broad older adult population | 10 high-income countries | RSV+hMPV combination | Product-switching scenario | Modelled |
| ██████████ | █████ | ████ | ██████ | $██m (base) |
| ██████████ | █████ | ████ | ██████ | $██m (upside) |
| Total addressable - base | 10 high-income countries | All profiles | All schedules | $███m |
What you receive
A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for decision-makers who need the full picture on the RSV older adult vaccine opportunity.
- Executive presentation (~375 slides, PDF) - disease background, epidemiology, incumbent sales trends, ACIP recommendation history, competitor pipeline and full commercial assessment with supporting narrative and references
- Interactive MS-Excel forecast model (~175 worksheets) - scenario-based volume and revenue outputs across 10 high-income countries, adjustable for revaccination schedule and combination-product switching
- Scenario-based commercial forecasts to 2037 - base, upside and conservative cases reflecting the post-2024 sales reset and the combination-vaccine pivot
- Competitor intelligence - GSK Arexvy, Pfizer Abrysvo, Moderna mResvia, AstraZeneca IVX-A12, Sanofi/Vicebio VXB-241, Moderna mRNA-1365 and Clover SCB-1019
- Updated epidemiology module - global and US adult RSV burden, underlying risk conditions, and the rationale for RSV/hMPV/PIV combination approaches
- Cost-effectiveness & product differentiation review - company-specific revenue and share estimates across USA, EU, developed ROW and emerging markets
Built for organisations weighing the RSV opportunity
Most valuable to teams evaluating the RSV older adult vaccine market against their own pipeline, BD ambitions or investment thesis, particularly in light of the 2024/25 sales reset and the emerging combination-vaccine pivot.
Vaccine developers
Positioning, commercial feasibility and target-population prioritisation for RSV and RSV/hMPV combination candidates at any stage.
Corporate strategy & BD
Validate the market size and structure after the 2024/25 sales reset, and understand what the combination-vaccine pivot means for share.
Investors & analysts
Independent assessment of market size and pipeline risk for due diligence on RSV and adjacent respiratory vaccine assets.
Public health & immunization programmes
Demand modelling for older adult and at-risk adult respiratory vaccination programmes.
Researchers & academia
Comprehensive epidemiology and vaccine landscape for grant and translational planning, including the RSV/hMPV/PIV combination rationale.
Market access & policy
Pricing benchmarks and access-pathway assumptions across public and private older adult immunization channels.
VacZine Analytics has tracked Respiratory vaccine markets since our earliest editions, positioning us to reassess the RSV older adult opportunity the moment incumbent sales trends and ACIP guidance began to shift. This analysis combines a rigorous epidemiological and clinical review with an independently constructed commercial model spanning 10 high-income countries and adjustable revaccination schedules that most forecasts model only in aggregate. Few groups have followed this market as closely or for as long, and that recognised, independent expertise underpins everything in the analysis, which has been well received by clients across the field.
This August 2025 edition incorporates full-year sales trends for Arexvy, Abrysvo and mResvia, ACIP's April 2025 expansion to at-risk 50 to 59 year-olds, and the latest combination-vaccine data from AstraZeneca, Sanofi/Vicebio and Moderna. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.
Syndicate the refresh - or commission the answer you need
Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc RSV analysis, a briefing call is included on request.